Moleculin to Present at the H.C. Wainwright BioConnect Conference

Rhea-AI Summary

Moleculin Biotech, Inc. (Nasdaq: MBRX) announced that President and CEO Walter Klemp will present at the virtual H.C. Wainwright BioConnect Conference from January 10-13, 2022. The presentation will be available on-demand starting January 10, 2022, at 7:00 AM ET for registered participants and accessible on the Company's website for 90 days thereafter. Moleculin is focused on developing a portfolio of drug candidates targeting resistant tumors and viruses, including Annamycin for acute myeloid leukemia and WP1066 for various cancers.

HOUSTON, Jan. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the virtual H.C. Wainwright BioConnect Conference taking place January 10-13, 2022.

A video webcast of the presentation will be available for viewing on-demand beginning Monday, January 10, 2022, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company's website (www.moleculin.com). The webcast replay will be archived for 90 days following the event.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.

For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.

Investor Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-to-present-at-the-hc-wainwright-bioconnect-conference-301456185.html

SOURCE Moleculin Biotech, Inc.

FAQ

When will Moleculin Biotech present at the H.C. Wainwright BioConnect Conference?

Moleculin Biotech will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022.

Where can I watch the Moleculin Biotech presentation?

The presentation will be available on-demand starting January 10, 2022, at 7:00 AM ET on the Company's website.

What is the focus of Moleculin Biotech's drug development?

Moleculin Biotech focuses on developing drug candidates targeting highly resistant tumors and viruses.

What are the key drugs in Moleculin Biotech's portfolio?

Key drugs include Annamycin for acute myeloid leukemia and WP1066 for targeting various cancers.

How long will the webcast of the Moleculin presentation be available?

The webcast replay will be archived for 90 days following the event.